Goserelin

FDA approved

Goserelin (Zoladex) is a GnRH agonist given as a small implant under the skin, approved by the FDA in 1989 for prostate cancer, breast cancer and endometriosis.

At a glance

Where it acts: Sexual & reproductive
Regulatory status: FDA approvedApproved by the U.S. FDA for at least one medical use.

Mechanism of Action

Goserelin is a 10-amino acid GnRH analog released slowly from a biodegradable implant. Continuous stimulation of pituitary GnRH receptors desensitizes them, suppressing LH and FSH and lowering testosterone or estrogen to castration levels.

Typical Dosage (Research)

Prescription-only medicine. Dosing is set by a physician according to the FDA-approved label and the condition being treated.

Side Effects & Risks

Hot flashes, sexual dysfunction, sweating, mood changes and implant site reactions.

Bone loss, high blood sugar, cardiovascular risk with androgen deprivation, and injury to blood vessels at the implant site.

Who Uses Goserelin

Men with prostate cancer; premenopausal women with advanced breast cancer or endometriosis.